Interpretation of Research on the Efficacy and Safety of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma Following Anti-BCMA Therapies Academic Background Multiple myeloma (MM) is a malignancy stemming from plasma cells within the bone marrow. Recent advancements in treatment have significantly improved overall survival rates. How...

Stage-specific Chromosomal Deletions Activate the IRX3 Oncogene in T-cell Acute Lymphoblastic Leukemia In the field of cancer research, understanding regulatory mechanisms of the noncoding genome remains a key focus, especially concerning how oncogenes can be aberrantly activated through non-canonical regulatory pathways. This paper, authored by Su...

The Incidence, Risk Factors, and Prognostic Impact of Bleeding Risk in Cancer Patients: A Review of the Vienna Cancer, Thrombosis, and Bleeding Study Academic Background and Research Motivation Cancer patients frequently experience hemostatic dysregulation, yet existing research has primarily focused on cancer-associated venous thromboembolism (VTE...

Report on the Academic Paper on the Monoclonal Antibody INCA033989 for Targeting Mutated Calreticulin in Myeloid Tumors Background: Calreticulin Mutation-Driven Myeloproliferative Neoplasms Myeloproliferative neoplasms (MPNs) are hematological malignancies caused by somatic mutations occurring in multipotent hematopoietic stem cells (HSCs). These m...

Review of the Study on Antimetabolite Dose Intensity and Adverse Outcomes in Children with Acute Lymphoblastic Leukemia (ALL) Background and Research Question Acute Lymphoblastic Leukemia (ALL) is the most common form of leukemia in children. Current treatment strategies include risk-based induction therapy, response-adapted post-induction therapy,...

Genetic Risk Stratification and Outcomes Among Treatment-Naive AML Patients Treated with Venetoclax and Azacitidine Academic Background Acute myeloid leukemia (AML) is a highly heterogeneous hematologic malignancy, with prognosis closely related to the genetic characteristics of patients. The European LeukemiaNet (ELN) 2017 and 2022 risk stratifica...

Daratumumab in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: The DELPHINUS Study Academic Background Acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL) are among the most common malignancies in children. Although the cure rate for newly diagnosed ALL and LL patients is relatively high, 10% to ...

Academic Background Conjunctival Melanoma (COM) is a rare but potentially lethal ocular cancer, particularly when metastasis occurs, with limited treatment options. Although current treatments for primary conjunctival melanoma are relatively effective, once metastasis occurs, patient survival rates drop significantly, with most patients surviving l...

Academic Background and Problem Statement Arteriovenous Malformations (AVMs) are benign vascular anomalies prone to pain, bleeding, and progressive growth. The primary cause of AVMs is somatic mutations in the RAS-MAPK signaling pathway. However, not all patients have identifiable causative mutations. To further explore the pathogenesis of AVMs, re...

Prevalence and Clinical Significance of Claudin-3 Expression in Cancer: A Tissue Microarray Study on 14,966 Tumor Samples Academic Background Claudin-3 (Cldn3) is a member of the Claudin family, involved in the formation of tight junctions (TJs), which regulate intercellular permeability. TJs play a crucial role in maintaining the barrier function ...